Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2019 Earnings Conference Call - Final Transcript
Mar 03, 2020 • 04:30 pm ET
Good day, everyone, and welcome to the Syndax Fourth Quarter 2019 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Claudia Styslinger of Argot Partners. Please begin.
Thank you, operator. Welcome, and thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax' fourth quarter and full year 2019 financial and operating results.
I'm Claudia Styslinger with Argot Partners. And with me this afternoon to discuss the results and provide an update on the company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Rick Shea, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Michael Metzger, President and Chief Operating Officer; and Dr. Michael Meyers, Chief Medical Officer. This call is being accompanied by a slide deck that has been posted on the company's website, so I'd ask you to please turn to our forward-looking statements on Slide 2.
Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in the company's most recent quarterly report on Form 10-Q as well as other reports filed with the SEC. Any forward-looking statements represent our views as of today, March 3, 2020, only. A replay of this call will be available on the company's website, www.syndax.com, following this call.
With that, I am pleased to turn the call over to Dr. Briggs Morrison, Chief Executive Officer of Syndax. Briggs?
Briggs W. Morrison
Thank you, Claudia, and thank you to everyone joining us on today's call and the webcast. Slide 3 provides a high-level summary of our current corporate priorities as we strive to realize a future in which people with cancer live longer and better than ever before. We made great progress in 2019 in all 3 of our programs. Since our last call in November of 2019, we have announced clinical data demonstrating proof-of-concept for the use of our anti-CSF-1R antibody, axatilamab, in the treatment of chronic graft versus host disease. We've announced 2 premier scientific publications that add to the compelling preclinical data supporting the potential of our Menin inhibitor to be an effective therapy in acute leukemia, and we announced the addition of $55 million to our balance sheet.
I think 2020 will be a tremendously exciting and transformative year for our company. First, we know that the final overall survival readout of E2112 will occur this year, bringing us closer to a potential near-term FDA filing, approval and launch in hormone receptor positive metastatic breast cancer. Second, the Phase I AUGMENT 101 trial of our highly selective, rationally designed Menin inhibitor, SNDX-5613, is underway, and we expect meaningful data from